On October 10, AnaptysBio Inc. (ANAB) reported positive results from its Phase 2a clinical trial of a drug to treat atopic dermatitis. Based on the current clinical trial results, the efficacy of this drug is much higher than other similar drugs on the market for the treatment of moderate-to-severe atopic dermatitis. Multiple studies also indicate […]
Sensor systems developer, FLIR Systems (FLIR), landed a $74.7 million contract with the U.S. military on October 2. They will provide TacFLIR surveillance cameras in support of the U.S. Army EO/IR-Force Protection (FP) program. Sonal detected the event and sent an alert at 8:00 am. The next trade occurred during the pre-market trading hours […]
On September 29, the FDA approved Novo-Nordisk’s (NVO) new drug to treat diabetes. Fiasp is fast-acting insulin that controls post-meal spikes in blood sugar. It works faster than existing drugs on the market and is already approved in both Canada and Europe. Sonal caught the news and sent an alert at 11:03 am. The […]
On September 29, Zogenix (ZGNX) reported positive results from its phase 3 clinical trial for the drug ZX008. The drug treats a rare form of epilepsy known as Dravet Syndrome. Sonal caught the news at 7:00 am and sent out a level 2 alert. The stock price immediately surged but then faded after the […]
On October 2, Sangamo Biosciences (SGMO) and Bioverativ Inc. (BIVV) announced that the FDA accepted their application for an investigational new drug (IND). The drug, ST-400, is a gene-edited cell therapy candidate for people with transfusion-dependent-beta-thalassemia. There are about 100,000 patients being treated worldwide for this disease, which requires frequent blood transfusions. Sonal sent […]
On September 26, Akebia Therapeutics (AKBA) reported positive results from a phase 2 clinical trial of the drug Vadadustat. The study results came from Japanese patients with anemia associated with non-dialysis chronic kidney disease and confirmed prior findings. Sonal detected the event and sent out an alert at 7:00 am. The next trade occurred […]
On September 12, BRT Apartments, Inc. announced that it would be paying a quarterly dividend of $0.18 per share to its stockholders and that it would be renewing its stock repurchase program. BRT is a real estate investment trust that has not paid a dividend since September 2009. The company may buy back up to […]
On September 12, Aldeyra Therapeutics reported positive results from its clinical trial of a treatment for dry eye disease. The company plans to continue its phase 2 clinical trials in early 2018. The news triggered a Sonal level 2 alert at 7:00 am before the stock price rose from $4. The stock price surged over […]
On September 20, Alnylam Pharmaceuticals (ALNY) reported exciting stage 3 clinical trial results. Its drug, patisiran, treats a rare nerve disorder called familial amyloid polyneuropathy. Alnylam will seek regulatory approval for patisiran later this year. Sonal sent out a level 2 alert at 7 am, and the next trade was at $93.50. The price rose […]
After the close of the markets on September 21, AECOM (ACM) unveiled a new capital allocation policy and stock repurchase program. AECOM is a global infrastructure firm that plans to spend all available free cash flow to pay down debt until reaching a target level sometime in 2018. This plan includes a stock repurchase program […]
On September 20, Quad Graphics reported that it landed a $450 million printing contract. The Minnesota-based company will print all catalogs for the online retailer and fellow Minnesotans, Bluestem Brands, Inc. The news triggered a level 3 Sonal alert at 4:05 pm. The next trade occurred at 4:13 pm in after-hours trading for $20.1645. […]
Let us send you a summary of the signals Sonal generates EVERY WEEK… and you can decide if you’re missing anything.